Department of Medical Oncology, Dana Farber Cancer Institute, USA.
Indian J Pharmacol. 2011 Nov;43(6):624-7. doi: 10.4103/0253-7613.89814.
Potential of nonantibiotic therapies for treatment of Helicobacter pylori-related acid peptic disease remains underexplored. Several clinical studies have shown that higher prevalence of H. pylori infection is associated with low Vitamin C (Vit C) level in serum and gastric juice. However, there is no consensus regarding the usefulness of Vit C supplementation in the management of H. pylori infection. Surveying the existing literature we conclude that high concentration of Vit C in gastric juice might inactivate H. pylori urease, the key enzyme for the pathogen's survival and colonization into acidic stomach. Once infection established, urease is not very important for its survival. The role of Vit-C as anti-H. pylori agent in peptic ulcer diseases appears to be preventive rather than curative. Rather than supplementing high dose of Vit C along with conventional triple therapy, it is preferable to complete the conventional therapy and thereafter start Vit C supplementation for extended period which would prevent reinfection in susceptible individuals, provided the patients are not achlorhydric. Further studies are required to prove the role of Vit C in susceptible population.
非抗生素疗法治疗幽门螺杆菌相关酸相关消化性疾病的潜力仍未得到充分探索。多项临床研究表明,血清和胃液中维生素 C(Vit C)水平较低与幽门螺杆菌感染的高患病率相关。然而,关于 Vit C 补充在幽门螺杆菌感染管理中的作用尚未达成共识。通过对现有文献的调查,我们得出结论,高浓度的 Vit C 可能会使胃中的幽门螺杆菌尿素酶失活,尿素酶是该病原体生存和定植于酸性胃中的关键酶。一旦感染建立,尿素酶对其生存就不是很重要了。Vit-C 作为消化性溃疡疾病中的抗幽门螺杆菌药物的作用似乎是预防性的,而不是治疗性的。与常规三联疗法一起补充大剂量的 Vit C 相比,最好在完成常规治疗后开始延长 Vit C 补充期,这将预防易感个体的再次感染,前提是患者没有胃酸缺乏症。需要进一步的研究来证明 Vit C 在易感人群中的作用。